Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting

Abstract Background The morbidity and mortality of adult diseases caused by S. pneumoniae increase with age and presence of underlying chronic diseases. Currently, two vaccine technologies against S. pneumoniae are used: the 23-valent pneumococcal polysaccharide vaccine (PPV23) and the pneumococcal...

Full description

Bibliographic Details
Main Authors: Mikkelsen Malene B, Husby Oyvind, Molden Tor, Mwaura David N, Olsen Jens, Kristensen Nanna V, Vietri Jeffrey
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Pneumococcal diseases
Pneumococcal infection
Vaccination
Cost-utility analysis
PCV20
20-valent pneumococcal conjugate vaccine
Online Access:https://doi.org/10.1186/s12962-023-00458-4

Internet

https://doi.org/10.1186/s12962-023-00458-4

Similar Items